Qiagen, Tracer Biotechnologies announce strategic partnership
Confident Investing Starts Here:
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 hours ago
- Yahoo
India In Vitro Diagnostics (IVD) Industry Analysis & Forecast (2025-2034) Featuring Roche, Transasia Bio-Medicals, Bio-Rad Labs, BioMerieux, Sysmex, Abbott, Thermo Fisher Scientific, QIAGEN, Quidel, Danaher
The market's 6.10% CAGR reflects advances in molecular diagnostics, healthcare infrastructure expansion, and personalized medicine. Key trends include companies like Sysmex enhancing local operations and WHO expanding diabetes-related IVDs. Abbott, Qiagen, Quidel, and Danaher lead the market's innovation-driven growth. Dublin, July 21, 2025 (GLOBE NEWSWIRE) -- The "India In Vitro Diagnostics Market Report and Forecast 2025-2034" has been added to offering. The India in vitro diagnostics (IVD) market, valued at USD 2.64 billion in 2024, is foreseen to grow at a CAGR of 6.10% from 2025 to 2034, potentially reaching USD 4.77 billion by the end of the period. This growth is primarily driven by the rising prevalence of chronic diseases, government initiatives, technological advancements, and the integration of personalized medicine into healthcare systems. This report answers pivotal questions about market valuation, growth forecasts, key demand drivers, current trends, segment leadership, technology and application dominance, and challenges. It also explores key players' strategies and the impact of strategic partnerships and mergers on market dynamics. Market Overview The IVD sector in India plays a crucial role in preventive healthcare, disease management, and personalized medicine. Driven by increased healthcare awareness and technological advancements in diagnostic technologies, the market is set for significant expansion. Government efforts to enhance healthcare infrastructure and focus on early, precise diagnostics are further powering its growth. Growth Drivers The surge in chronic and non-communicable diseases (NCDs) forms a fundamental growth driver for the IVD market in India. These conditions demand early and accurate diagnosis, thereby elevating the demand for cutting-edge diagnostic technologies. According to India's Ministry of Science and Technology, NCDs account for a substantial portion of mortality and disability, necessitating improved diagnostic solutions. Market Trends Several trends are shaping the market, including the localization of operations by IVD companies and the development of disease-specific IVD solutions. For instance, Sysmex India's commitment to establishing local manufacturing facilities marks a shift towards direct operations, which enhances product availability and customer support. Additionally, the expanding scope of disease-specific diagnostics, such as the WHO's inclusion of diabetes-related tests in its prequalification scope, underscores the market's evolution towards targeted healthcare solutions. Market Segmentation The market is segmented based on products and services (reagents and kits, instruments, software and services), technology (immunodiagnostics, molecular diagnostics, clinical chemistry, among others), application (infectious diseases, diabetes, oncology, and more), end user (hospitals, diagnostic centers, point-of-care testing, etc.), and regions (Northern and Central, Southern, Eastern, Western). Reagents and Kits Segment Dominance The reagents and kits segment leads due to their fundamental role in diagnostic testing. Innovations like Cipla Limited's RT-Direct multiplex COVID-19 RT-PCR test kit highlight the segment's importance, driven by advancements in point-of-care testing technologies and the growing prevalence of chronic and infectious diseases. Key Players Major companies influencing the India IVD market include Abbott, known for its innovative molecular diagnostics; Qiagen, enhancing laboratory efficiency with upcoming automated instruments; Quidel Corporation, offering specialized immunoassays; and Danaher Corporation, addressing chronic disease challenges through advanced diagnostics. Other notable players are F. Hoffmann-La Roche Ltd, Transasia Bio-Medicals Ltd, Bio-Rad Laboratories, Inc., bioMerieux SA, Thermo Fisher Scientific Inc., and Sysmex Corporation. Key Attributes Report Attribute Details No. of Pages 250 Forecast Period 2025-2034 Estimated Market Value (USD) in 2025 $2.64 Billion Forecasted Market Value (USD) by 2034 $4.77 Billion Compound Annual Growth Rate 6.1% Regions Covered India Key Topics Covered Preface Objectives of the Study Key Assumptions Report Coverage - Key Segmentation and Scope Research Methodology Executive Summary In Vitro Diagnostics Market Overview Asia Pacific In Vitro Diagnostics Market Overview India In Vitro Diagnostics Market Overview Vendor Positioning Analysis Key Vendors Prospective Leaders Niche Leaders Disruptors India In Vitro Diagnostics Market Landscape India In Vitro Diagnostics Market: Developers Landscape India In Vitro Diagnostics Market: Product Landscape India In Vitro Diagnostics Market Dynamics Market Drivers and Constraints SWOT Analysis PESTEL Analysis Porter's Five Forces Model Key Demand Indicators Key Price Indicators Industry Events, Initiatives, and Trends Value Chain Analysis India In Vitro Diagnostics Market Segmentation (2018-2034) India In Vitro Diagnostics Market by Product & Services India In Vitro Diagnostics Market by Technology India In Vitro Diagnostics Market by Application India In Vitro Diagnostics Market by End User India In Vitro Diagnostics Market by Region Regulatory Framework Funding and Investment Analysis Analysis by Funding Instances Analysis by Type of Funding Analysis by Funding Amount Analysis by Leading Players Analysis by Leading Investors Analysis by Geography Strategic Initiatives Analysis by Partnership Instances Analysis by Type of Initiatives Analysis by Joint Ventures Analysis by Leading Players Analysis by Geography Supplier Landscape Market Share Analysis (Top 5 Companies) F. Hoffmann-La Roche Ltd. Transasia Bio-Medicals Ltd. Bio-Rad Laboratories, Inc. BioMerieux SA Sysmex Corporation Abbott Thermo Fisher Scientific Inc. QIAGEN Quidel Corporation Danaher Corporation India In Vitro Diagnostics Market - Distribution Model (Additional Insight) Overview Potential Distributors Key Parameters for Distribution Partner Assessment Key Opinion Leaders (KOL) Insights (Additional Insight) For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
19 hours ago
- Yahoo
India In Vitro Diagnostics (IVD) Industry Analysis & Forecast (2025-2034) Featuring Roche, Transasia Bio-Medicals, Bio-Rad Labs, BioMerieux, Sysmex, Abbott, Thermo Fisher Scientific, QIAGEN, Quidel, Danaher
The market's 6.10% CAGR reflects advances in molecular diagnostics, healthcare infrastructure expansion, and personalized medicine. Key trends include companies like Sysmex enhancing local operations and WHO expanding diabetes-related IVDs. Abbott, Qiagen, Quidel, and Danaher lead the market's innovation-driven growth. Dublin, July 21, 2025 (GLOBE NEWSWIRE) -- The "India In Vitro Diagnostics Market Report and Forecast 2025-2034" has been added to offering. The India in vitro diagnostics (IVD) market, valued at USD 2.64 billion in 2024, is foreseen to grow at a CAGR of 6.10% from 2025 to 2034, potentially reaching USD 4.77 billion by the end of the period. This growth is primarily driven by the rising prevalence of chronic diseases, government initiatives, technological advancements, and the integration of personalized medicine into healthcare systems. This report answers pivotal questions about market valuation, growth forecasts, key demand drivers, current trends, segment leadership, technology and application dominance, and challenges. It also explores key players' strategies and the impact of strategic partnerships and mergers on market dynamics. Market Overview The IVD sector in India plays a crucial role in preventive healthcare, disease management, and personalized medicine. Driven by increased healthcare awareness and technological advancements in diagnostic technologies, the market is set for significant expansion. Government efforts to enhance healthcare infrastructure and focus on early, precise diagnostics are further powering its growth. Growth Drivers The surge in chronic and non-communicable diseases (NCDs) forms a fundamental growth driver for the IVD market in India. These conditions demand early and accurate diagnosis, thereby elevating the demand for cutting-edge diagnostic technologies. According to India's Ministry of Science and Technology, NCDs account for a substantial portion of mortality and disability, necessitating improved diagnostic solutions. Market Trends Several trends are shaping the market, including the localization of operations by IVD companies and the development of disease-specific IVD solutions. For instance, Sysmex India's commitment to establishing local manufacturing facilities marks a shift towards direct operations, which enhances product availability and customer support. Additionally, the expanding scope of disease-specific diagnostics, such as the WHO's inclusion of diabetes-related tests in its prequalification scope, underscores the market's evolution towards targeted healthcare solutions. Market Segmentation The market is segmented based on products and services (reagents and kits, instruments, software and services), technology (immunodiagnostics, molecular diagnostics, clinical chemistry, among others), application (infectious diseases, diabetes, oncology, and more), end user (hospitals, diagnostic centers, point-of-care testing, etc.), and regions (Northern and Central, Southern, Eastern, Western). Reagents and Kits Segment Dominance The reagents and kits segment leads due to their fundamental role in diagnostic testing. Innovations like Cipla Limited's RT-Direct multiplex COVID-19 RT-PCR test kit highlight the segment's importance, driven by advancements in point-of-care testing technologies and the growing prevalence of chronic and infectious diseases. Key Players Major companies influencing the India IVD market include Abbott, known for its innovative molecular diagnostics; Qiagen, enhancing laboratory efficiency with upcoming automated instruments; Quidel Corporation, offering specialized immunoassays; and Danaher Corporation, addressing chronic disease challenges through advanced diagnostics. Other notable players are F. Hoffmann-La Roche Ltd, Transasia Bio-Medicals Ltd, Bio-Rad Laboratories, Inc., bioMerieux SA, Thermo Fisher Scientific Inc., and Sysmex Corporation. Key Attributes Report Attribute Details No. of Pages 250 Forecast Period 2025-2034 Estimated Market Value (USD) in 2025 $2.64 Billion Forecasted Market Value (USD) by 2034 $4.77 Billion Compound Annual Growth Rate 6.1% Regions Covered India Key Topics Covered Preface Objectives of the Study Key Assumptions Report Coverage - Key Segmentation and Scope Research Methodology Executive Summary In Vitro Diagnostics Market Overview Asia Pacific In Vitro Diagnostics Market Overview India In Vitro Diagnostics Market Overview Vendor Positioning Analysis Key Vendors Prospective Leaders Niche Leaders Disruptors India In Vitro Diagnostics Market Landscape India In Vitro Diagnostics Market: Developers Landscape India In Vitro Diagnostics Market: Product Landscape India In Vitro Diagnostics Market Dynamics Market Drivers and Constraints SWOT Analysis PESTEL Analysis Porter's Five Forces Model Key Demand Indicators Key Price Indicators Industry Events, Initiatives, and Trends Value Chain Analysis India In Vitro Diagnostics Market Segmentation (2018-2034) India In Vitro Diagnostics Market by Product & Services India In Vitro Diagnostics Market by Technology India In Vitro Diagnostics Market by Application India In Vitro Diagnostics Market by End User India In Vitro Diagnostics Market by Region Regulatory Framework Funding and Investment Analysis Analysis by Funding Instances Analysis by Type of Funding Analysis by Funding Amount Analysis by Leading Players Analysis by Leading Investors Analysis by Geography Strategic Initiatives Analysis by Partnership Instances Analysis by Type of Initiatives Analysis by Joint Ventures Analysis by Leading Players Analysis by Geography Supplier Landscape Market Share Analysis (Top 5 Companies) F. Hoffmann-La Roche Ltd. Transasia Bio-Medicals Ltd. Bio-Rad Laboratories, Inc. BioMerieux SA Sysmex Corporation Abbott Thermo Fisher Scientific Inc. QIAGEN Quidel Corporation Danaher Corporation India In Vitro Diagnostics Market - Distribution Model (Additional Insight) Overview Potential Distributors Key Parameters for Distribution Partner Assessment Key Opinion Leaders (KOL) Insights (Additional Insight) For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
08-07-2025
- Yahoo
QIAGEN N.V. to Release Results for Q2 2025 and Hold Webcast
VENLO, Netherlands, July 08, 2025--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the second quarter of 2025. Press release date / time: Tuesday, August 5, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Wednesday, August 6, at 15:30 Frankfurt time / 14:30 London time / 09:30 New York time. Three options for joining the conference call Register for call back connection - Click here: Connect me Service is available 15 minutes before the call starts Dial-in by phoneU.S.: +1 929 477 0402UK: +44 (0)330 165 3655GER: +49 (0)69 6610 2480Conference ID: 1992038To avoid waiting time, please join the event conference 5-10 minutes prior to the start time. Access the audio webcast - Click here: Access Webcast A conference call replay will be available by using the following link: Contact: IR@ About QIAGEN QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions, enabling customers to extract and gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis while bioinformatics software and knowledge bases can be used to interpret data to find actionable insights. Automation solutions bring these processes together into seamless and costeffective workflows. QIAGEN serves over 500,000 customers globally in Life Sciences (academia, pharma R&D and industrial applications, primarily forensics) and Molecular Diagnostics for clinical healthcare. As of March 31, 2025, QIAGEN employed more than 5,600 people in over 35 locations worldwide. For more information, visit category: Financial View source version on Contacts John GilardiVice President Head of Corporate Communications+49 2103 29 11711+49 152 018 11711+1 240 686 2222Email: ir@ Domenica MartoranaAssociate Director Investor Relations+49 2103 29 11244+49 152 018 11244Email: ir@
